Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer
Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | Prostate Cancer |
| Online Access: | http://dx.doi.org/10.1155/2014/230812 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832545417220325376 |
|---|---|
| author | Lior Z. Braunstein Ming-Hui Chen Marian Loffredo Philip W. Kantoff Anthony V. D'Amico |
| author_facet | Lior Z. Braunstein Ming-Hui Chen Marian Loffredo Philip W. Kantoff Anthony V. D'Amico |
| author_sort | Lior Z. Braunstein |
| collection | DOAJ |
| description | Background. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain of ≥10 lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received was associated with this endpoint adjusting for known prognostic factors. Results. By the 6-month followup, 12 men gained ≥10 lbs, of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared to RT + ADT were less likely to gain ≥10 lbs (adjusted odds ratio (AOR): 0.18 [95% CI: 0.04–0.89]; P=0.04), whereas this risk increased with increasing BMI (AOR: 1.15 [95% CI: 1.01–1.31]; P=0.04). Conclusions. Consideration should be given to avoid ADT in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened life expectancy from weight gain is expected. |
| format | Article |
| id | doaj-art-0a39f8b7195b466aba14a66d643d01a4 |
| institution | Kabale University |
| issn | 2090-3111 2090-312X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Prostate Cancer |
| spelling | doaj-art-0a39f8b7195b466aba14a66d643d01a42025-02-03T07:25:42ZengWileyProstate Cancer2090-31112090-312X2014-01-01201410.1155/2014/230812230812Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate CancerLior Z. Braunstein0Ming-Hui Chen1Marian Loffredo2Philip W. Kantoff3Anthony V. D'Amico4Harvard Radiation Oncology Program, Brigham and Women’s Hospital, ASB-I Radiation Oncology L2, 75 Francis Street, Boston, MA 02115, USADepartment of Statistics, University of Connecticut, 215 Glenbrook Road, U-4120, Storrs, CT 06269-4120, USALank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USALank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USALank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, Mailstop Dana 1230, 450 Brookline Avenue, Boston, MA 02215, USABackground. Increasing body mass index (BMI) is associated with increased risk of mortality; however, quantifying weight gain in men undergoing androgen deprivation therapy (ADT) for prostate cancer (PC) remains unexplored. Methods. Between 1995 and 2001, 206 men were enrolled in a randomized trial evaluating the survival difference of adding 6 months of ADT to radiation therapy (RT). BMI measurements were available in 171 men comprising the study cohort. The primary endpoint was weight gain of ≥10 lbs by 6-month followup. Logistic regression analysis was performed to assess whether baseline BMI or treatment received was associated with this endpoint adjusting for known prognostic factors. Results. By the 6-month followup, 12 men gained ≥10 lbs, of which 10 (83%) received RT + ADT and, of these, 7 (70%) were obese at randomization. Men treated with RT as compared to RT + ADT were less likely to gain ≥10 lbs (adjusted odds ratio (AOR): 0.18 [95% CI: 0.04–0.89]; P=0.04), whereas this risk increased with increasing BMI (AOR: 1.15 [95% CI: 1.01–1.31]; P=0.04). Conclusions. Consideration should be given to avoid ADT in obese men with low- or favorable-intermediate risk PC where improved cancer control has not been observed, but shortened life expectancy from weight gain is expected.http://dx.doi.org/10.1155/2014/230812 |
| spellingShingle | Lior Z. Braunstein Ming-Hui Chen Marian Loffredo Philip W. Kantoff Anthony V. D'Amico Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer Prostate Cancer |
| title | Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer |
| title_full | Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer |
| title_fullStr | Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer |
| title_full_unstemmed | Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer |
| title_short | Obesity and the Odds of Weight Gain following Androgen Deprivation Therapy for Prostate Cancer |
| title_sort | obesity and the odds of weight gain following androgen deprivation therapy for prostate cancer |
| url | http://dx.doi.org/10.1155/2014/230812 |
| work_keys_str_mv | AT liorzbraunstein obesityandtheoddsofweightgainfollowingandrogendeprivationtherapyforprostatecancer AT minghuichen obesityandtheoddsofweightgainfollowingandrogendeprivationtherapyforprostatecancer AT marianloffredo obesityandtheoddsofweightgainfollowingandrogendeprivationtherapyforprostatecancer AT philipwkantoff obesityandtheoddsofweightgainfollowingandrogendeprivationtherapyforprostatecancer AT anthonyvdamico obesityandtheoddsofweightgainfollowingandrogendeprivationtherapyforprostatecancer |